MRZM News and Press, Marizyme Inc From 11/06/20

Marizyme (MRZM) has appointed veteran life sciences executive and investor Dr. Neil J. Campbell, as CEO and President and a member of its Board of Directors. Dr. Campbell currently serves as Chairman of Mosaigen, a commercial development company, and RespaRx, a medical device company.Press re...

Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors Veteran Life Sciences Executive and Investor Brings 35+ Years' Experience PR Newswire JUPITER, Fla., Nov. 6, 2020 JUPITER, Fla. , Nov. 6, 2020 /PRNewswire/ --...

JUPITER, FL / ACCESSWIRE / October 27, 2020 / Marizyme, Inc. (OTCQB:MRZM) ("Marizyme" or the "Company"), an integrated life sciences company, announced today that it has signed a binding letter of intent with SBH Nutrition Science LLC ("SBH") to develop pet therapeutic products using Marizym...

JUPITER, FL / ACCESSWIRE / October 9, 2020 / Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB:MRZM) is a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications. Today, Marizy...

JUPITER, FL / ACCESSWIRE / September 29, 2020 / Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTCQB:MRZM) company focused on acquiring late-stage drug and medical device assets announced today that it has completed the acquisition of all or substantially all of the Somahlu...

DAVENPORT, Fla. , Oct. 11, 2019 /PRNewswire/ -- Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC:MRZM) company focused on acquiring late-stage drug assets to develop for use in the acute care space, announced today that they have agreed to exclusively distribute Somahl...

Sacramento, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Spotlight Growth has published new content on Marizyme, Inc. ("Marizyme" or the "Company") (OTC Pink: MRZM), a biotechnology company focused on its clinically-tested and patented use of protease therapeutic platform...

FORT COLLINS, CO / ACCESSWIRE / March 18, 2019 / Marizyme, Inc. (''Marizyme'' or the ''Company''), a publicly traded (OTC PINK: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space and related areas, announced today that they signed a Letter of Intent ...

FORT COLLINS, CO / ACCESSWIRE / March 15, 2019 / Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC PINK: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that they have recei...

Sacramento, CA, March 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Spotlight Growth has published new content on Marizyme, Inc. (“Marizyme” or the “Company”) (OTC Pink: MRZM), a biotechnology company focused on its clinically-tested and patented use of p...